Podcasts

E-Books

Videos

Articles

Clinical

European investigators have derived a set of core principals for developing higher utilization of biosimilars. 

Europeans Devise Checklist for Promoting Biosimilar Use

Tony Hagen is senior managing editor for The Center for Biosimilars

Biocon had a busy quarter, which included the launch of a long-acting insulin glargine product (Semglee) in partnership with Mylan.


Biocon Reports Biosimilars Revenue Growth

Sometimes the reference product exhibits pricing resistance against the competitive effect of biosimilars, according to a Pharmaceutical Strategies Group report.

Report: Specialty Drug Assessment Highlights Biosimilar Progress

A report from the IQVIA Institute for Human Data Science states that assessments of the health of the US biosimilar market are too conservative.

IQVIA: Biosimilars Could Save $100 Billion Over Next 5 Years

California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.

California's Governor Signs Bill for State to Produce Its Own Biosimilars, Insulins

A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.

Stakeholders Joust Over Biosimilar Availability at PCOC20 

Isha Bangia, PharmD, MBA, is a manager of US market access at Certara Evidence & Access. She received her PharmD from Rutgers University and an MBA from Johns Hopkins University. Her current responsibilities include optimizing product value stories and working with customers to improve access across the US healthcare system. Her experience includes practicing pharmacy, payer market research, and pharma strategy and analytics. Her work has covered many therapeutic areas, including biosimilars, oncology, diabetes, vaccines, and rare diseases.

Amgen's Onpro autoinjector device for pegfilgrastim is a stunning example of how product differentiation via drug delivery devices can protect market share in the biologics market.

Contributor: Drug Delivery Devices Help Originator Companies Retain Market Share

The American College of Physicians (ACP) said many reforms are needed to install appropriate checks and balances in the biologic drugs marketplace. 

ACP Calls for Biologics Marketplace Reforms

Representative Glenn Grothman, R-Wisconsin, says interchangeability for insulins makes sense based on the savings potential and safety record of these agents.

Rep Grothman Introduces Bill for Automatic Insulin Biosimilar Interchangeablity 

It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.
 

Diabetes